Volume 16, Issue 3
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
This issue showcases updates presented at the AIDS 2026 conference in Rio de Janeiro, Brazil. As the field continues to grapple with the impact of PEPFAR funding cuts on HIV services, amfAR shared their latest analysis from the PEPFAR Pulse Study. AVAC’s latest infographic unpacks the current status of generic licensing agreements for long-acting PrEP products, including alimatravir (AMI), reflecting significant progress in speeding up access as new products enter the market, while also highlighting persistent and worrying gaps in these agreements.
Recent trials on long-acting treatment and broadly neutralizing antibodies (bNAbs) for prevention were also shared at the conference. A new weekly pill for HIV treatment demonstrated non-inferiority, while a combination of two bNAbs did not provide protection from HIV. Both results provided important insights and implications for the current status of the HIV prevention and treatment pipelines.
Previous issues are available in our resource library.